Patents versus patients: reflections on this blatant patent regime Online publication date: Sun, 22-Mar-2009
by Aditi Agarwala, Akhil Prasad
International Journal of Liability and Scientific Enquiry (IJLSE), Vol. 2, No. 2, 2009
Abstract: The paper centres on the 'patents versus patients' debate and delves into the challenges facing India's pharmaceutical sector with the advent of the World Trade Organization (WTO)-Trade-Related Aspects of Intellectual Property Rights (TRIPS) product patent regime. Considering the nation's commitments on international soil and the subsequent domestic legislations enacted to fulfil commitments made at international level, it explores the legitimacy behind the unification of intellectual property laws at the global level and questions the 'one shoe fits all' regime. The famous Chennai High Court decision upholding the constitutional validity of domestic patent legislation upon being challenged by a Swiss pharmaceutical corporation has been discussed. Indeed, it is not easy to manage the challenges of WTO participation, where such is the price for innovation. Towards that end, the paper attempts to offer a package of solutions to be collectively administered in order to mitigate the ills of what has now become a 'harsh' patent regime.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Liability and Scientific Enquiry (IJLSE):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook